ArticleAmerican journal of translational research2026
Banxia Xiexin Decoction inhibits chemoresistance in gastric cancer by regulating BMSC-derived exosome-mediated G3BP1-YWHAZ protein interaction.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stress-specific 14-3-3-client modules in digestive cancers: an evidence-graded review of adaptive survival and therapy resistance.Cancer biology & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate whether Banxia Xiexin Decoction (BXD) reverses bone marrow mesenchymal stem cell (BMSC)-derived exosome-induced oxaliplatin resistance in gastric cancer (GC) and to elucidate the underlying mechanism.
methodsOxaliplatin-resistant HGC-27 cells and human BMSCs were cultured in vitro. Exosomes were isolated and characterized by transmission electron microscopy and marker analysis. Cell viability was assessed using CCK-8 assays. Apoptosis, multidrug resistance proteins (MDR, MRP, LRP), stress granule (SG) formation, and G3BP1-YWHAZ interaction were examined by flow cytometry, immunofluorescence, Western blotting, and co-immunoprecipitation. A nude mouse xenograft model was used to evaluate in vivo effects.
resultsBMSC-derived exosomes enhanced oxaliplatin resistance in HGC-27 cells, reduced apoptosis, upregulated MDR-related proteins, promoted SG formation, and strengthened G3BP1-YWHAZ interaction. BXD-containing serum reversed these effects by restoring apoptosis, increasing Bax and cleaved caspase expression, suppressing resistance-associated proteins and SG assembly, and disrupting G3BP1-YWHAZ binding. In vivo, BXD attenuated exosome-mediated chemoresistance, inhibited tumor growth, and enhanced oxaliplatin-induced apoptosis.
conclusionBMSC-derived exosomes promote oxaliplatin resistance in GC through activation of the G3BP1-YWHAZ axis. BXD restores chemosensitivity by interfering with this exosome-mediated pathway, supporting its use as a potential adjuvant strategy to overcome chemotherapy resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.